In Brief
This article was originally published in The Tan Sheet
Executive Summary
Perrigo cleared for Zegerid OTC equivalent; Abbott Nutrition feels effects of international distribution model shift; Supreme Court passes on McNeil Tylenol preemption case; Calif. class action proceeds against POM Wonderful; multivitamins yield modest cancer-prevention benefits; study links PSE buys, meth labs.
You may also be interested in...
In Brief
Sanofi picks up Colombian generics firm Genfar; judge defers to FTC adjudication in dismissing POM Wonderful suit; P&G sues BrushPoint over whitening strip patents; Colgate, Omron team on electronic toothbrushes; more news In Brief.
State Officials Urging Rx Pseudoephedrine Face Strong Lobby
Officials from Mississippi, Missouri, Oregon and South Carolina and the National Narcotics Officers Associations Coalition testifying before a House subcommittee call for moving all PSE products to prescription status.
In Brief
Novartis begins OTC recovery with Excedrin; Abbott Nutrition up double digits in Q2; trade groups discuss supplement GMPs with Sen. Durbin; ChromaDex licenses patents for nicotinamide riboside; Nature Made supplements alleged to contain pork by-products; more news In Brief.